Efficacy PROFILE

Explore Lumirix Efficacy

Half the patients who applied Ruxolitinib reached F-VASI75 at week 52.

Efficacy of Ruxolitinib Application on the Primary Endpoint F-VASI75 Response.

weekData

ᵃ Percentage calculated from pooled figures of the identical TRuE-V1 and TRuE-V2 study, rounded off to the nearest whole number.

Adapted from ref. 9

yearData

63.8%

of patients who applied Ruxolitinib cream since day 1 achieved F-VASI75 at week 104 (LTE end-of-treatment).

Reference:

10. Rosmarin D, Sebastian M, Amster M, et al. Facial and total vitiligo area scoring index response shift during 104 weeks of Ruxolitinib cream treatment for vitiligo: results from the open-label arm of the TRuE-V long-term extension phase 3 study. Presented at the American Academy of Dermatology Annual Meeting; March 17–21, 2023; New Orleans, LA.